[Second-line treatment with FOLFIRI plus aflibercept in a patient with right-sided, BRAF mutated metastatic colon cancer.]
This is the case report of a woman with more than 70 years and good PS, with diagnosis of right sided, BRAF mutated and MSI-high colon cancer, diffusively metastatic to lymph nodes. The treatment sequencing of FOLFOXIRI bevacizumab (I line) and FOLFIRI aflibercept (II line) allowed to maximally shrink the disease burden and dramatically extend survival thanks to the treatments' intensification (due to BRAF mutation-related aggressiveness) and the immune-modulating effects of anti-angiogenic treatments (due to immune-suppressive burden associated with MSI-high status).